Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gene Therapy
NIH, Gates launch $200 million project for HIV and sickle cell disease gene therapy
by Ryan Cross
November 2, 2019
| A version of this story appeared in
Volume 97, Issue 43
The National Institutes of Health and the Bill & Melinda Gates Foundation are committing $100 million each to develop affordable gene therapies for HIV and sickle cell disease. Sickle cell could be cured with gene-replacement or gene-editing approaches, and preclinical research indicates that CRISPR gene editing could chop up HIV genomes hiding in the body. Both programs will focus on in vivo therapies, in which cells are altered inside the body. The biggest challenge for both could be lowering manufacturing costs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X